<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30403909</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>07</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1555-8576</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Nov</Month>                        <Day>07</Day>                    </PubDate>                </JournalIssue>                <Title>Cancer biology &amp; therapy</Title>                <ISOAbbreviation>Cancer Biol. Ther.</ISOAbbreviation>            </Journal>            <ArticleTitle>A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study.</ArticleTitle>            <Pagination>                <MedlinePgn>1-9</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1080/15384047.2018.1523095</ELocationID>            <Abstract>                <AbstractText>We carried out a retrospective observational study of 264 HER2-positive advanced breast cancer (ABC) patients to explore the efficacy of first-line treatment with pertuzumab/trastuzumab/taxane in real-world setting. Survival data were analyzed by Kaplan Meier curves and log rank test. Median follow-up, length of pertuzumab/trastuzumab/taxane treatment and of pertuzumab, trastuzumab maintenance were 21, 4 and 15 months, respectively. The response rate was 77.3%, and the clinical benefit rate 93.6%. Median progression-free survival (mPFS) was 21 months, and median overall survival (mOS) was not reached. When comparing patients by trastuzumab-pretreatment, similar PFS were observed, although a longer OS was reached in trastuzumab-naïve patients (p = 0.02). Brain metastases at baseline and their development in course of therapy were associated with significantly shorter PFS (p = 0.0006) and shorter OS, although at a not fully statistically relevant extent (p = 0.06). The addition of maintenance endocrine therapy (ET) to pertuzumab/trastuzumab maintenance was associated with longer PFS (p = 0.0001), although no significant differences were detected in OS (p = 0.31). Results were confirmed by propensity score analysis (p = 0.003 and p = 0.46, respectively). In multivariate models, longer PFS was related to lower Performance Status (PS) (p = 0.07), metastatic stage at diagnosis (p = 0.006) and single metastatic site (p &lt; 0.0001). An OS advantage was observed with lower PS (p &lt; 0.0001), single metastatic site (p = 0.004), no prior exposure to trastuzumab (p = 0.004) and response to pertuzumab-based treatment (p = 0.003). Our results confirm that trastuzumab/pertuzumab/taxane is the standard of care as first-line treatment of patients with HER2-positive ABC even in the real-world setting. Moreover, the double-maintenance therapy (HER2 block and ET) is strongly recommended when feasible.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Gamucci</LastName>                    <ForeName>Teresa</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>a Medical Oncology Unit , ASL Frosinone , Frosinone , Italy.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>b Medical Oncology , Sandro Pertini Hospital , Roma , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Pizzuti</LastName>                    <ForeName>Laura</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>c Division of Medical Oncology 2 , IRCCS Regina Elena National Cancer Institute , Rome , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Natoli</LastName>                    <ForeName>Clara</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>d Department of Medical, Oral and Biotechnological Sciences , Centro Scienze dell'Invecchiamento e Medicina Traslazionale -CeSI-MeT , Chieti , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mentuccia</LastName>                    <ForeName>Lucia</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>a Medical Oncology Unit , ASL Frosinone , Frosinone , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sperduti</LastName>                    <ForeName>Isabella</ForeName>                    <Initials>I</Initials>                    <AffiliationInfo>                        <Affiliation>e Bio-Statistics Unit , IRCCS Regina Elena National Cancer Institute , Rome , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Barba</LastName>                    <ForeName>Maddalena</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>c Division of Medical Oncology 2 , IRCCS Regina Elena National Cancer Institute , Rome , Italy.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>f Scientific Direction , IRCCS Regina Elena National Cancer Institute , Rome , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sergi</LastName>                    <ForeName>Domenico</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>c Division of Medical Oncology 2 , IRCCS Regina Elena National Cancer Institute , Rome , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Iezzi</LastName>                    <ForeName>Laura</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>d Department of Medical, Oral and Biotechnological Sciences , Centro Scienze dell'Invecchiamento e Medicina Traslazionale -CeSI-MeT , Chieti , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Maugeri-Saccà</LastName>                    <ForeName>Marcello</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>c Division of Medical Oncology 2 , IRCCS Regina Elena National Cancer Institute , Rome , Italy.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>f Scientific Direction , IRCCS Regina Elena National Cancer Institute , Rome , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Vaccaro</LastName>                    <ForeName>Angela</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>a Medical Oncology Unit , ASL Frosinone , Frosinone , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Magnolfi</LastName>                    <ForeName>Emanuela</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>a Medical Oncology Unit , ASL Frosinone , Frosinone , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gelibter</LastName>                    <ForeName>Alain</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>g Medical Oncology Unit , Policlinico Umberto I , Rome , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Barchiesi</LastName>                    <ForeName>Giacomo</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>g Medical Oncology Unit , Policlinico Umberto I , Rome , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Magri</LastName>                    <ForeName>Valentina</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>g Medical Oncology Unit , Policlinico Umberto I , Rome , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>D'Onofrio</LastName>                    <ForeName>Loretta</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>h Department of Oncology , University Campus Biomedico of Rome , Rome , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cassano</LastName>                    <ForeName>Alessandra</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>i Department of Medical Oncology , Policlinico Universitario &quot;A. Gemelli&quot; , Rome , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rossi</LastName>                    <ForeName>Ernesto</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>i Department of Medical Oncology , Policlinico Universitario &quot;A. Gemelli&quot; , Rome , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Botticelli</LastName>                    <ForeName>Andrea</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>j Department of Clinical and Molecular Medicine , &quot;Sapienza&quot; University of Rome, Azienda Ospedaliera Sant'Andrea , Rome , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Moscetti</LastName>                    <ForeName>Luca</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>k Division of Medical Oncology, Department of Oncology and Hematology , University Hospital of Modena , Modena , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Omarini</LastName>                    <ForeName>Claudia</ForeName>                    <Initials>C</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-2906-7896</Identifier>                    <AffiliationInfo>                        <Affiliation>k Division of Medical Oncology, Department of Oncology and Hematology , University Hospital of Modena , Modena , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fabbri</LastName>                    <ForeName>Maria Agnese</ForeName>                    <Initials>MA</Initials>                    <AffiliationInfo>                        <Affiliation>l Medical Oncology Unit , Belcolle Hospital , Viterbo , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Scinto</LastName>                    <ForeName>Angelo Fedele</ForeName>                    <Initials>AF</Initials>                    <AffiliationInfo>                        <Affiliation>m Medical Oncology Unit , San Pietro Fatebenefratelli Hospital , Rome , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Corsi</LastName>                    <ForeName>Domenico</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>m Medical Oncology Unit , San Pietro Fatebenefratelli Hospital , Rome , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Carbognin</LastName>                    <ForeName>Luisa</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>n U.O.C. Oncology , University of Verona, Azienda Ospedaliera Universitaria Integrata , Verona , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mazzotta</LastName>                    <ForeName>Marco</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>j Department of Clinical and Molecular Medicine , &quot;Sapienza&quot; University of Rome, Azienda Ospedaliera Sant'Andrea , Rome , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bria</LastName>                    <ForeName>Emilio</ForeName>                    <Initials>E</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-2333-704X</Identifier>                    <AffiliationInfo>                        <Affiliation>n U.O.C. Oncology , University of Verona, Azienda Ospedaliera Universitaria Integrata , Verona , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Foglietta</LastName>                    <ForeName>Jennifer</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>o Department of Medical Oncology , University of Perugia, Santa Maria della Misericordia Hospital , Perugia , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Samaritani</LastName>                    <ForeName>Riccardo</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>p Medical Oncology Unit , &quot;Regina Margherita&quot; Hospital , Rome , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Garufi</LastName>                    <ForeName>Carlo</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>q Division of Medical Oncology , Pescara Hospital , Pescara , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mariani</LastName>                    <ForeName>Luciano</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>r HPV Unit, Department of Gynaecologic Oncology , IRCCS Regina Elena National Cancer Institute , Rome , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Barni</LastName>                    <ForeName>Sandro</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>s Department of Oncology, Oncology Unit , ASST Bergamo Ovest , Treviglio , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mirabelli</LastName>                    <ForeName>Rosanna</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>t Department of Hematology &amp; Oncology , Azienda Ospedaliera Pugliese-Ciaccio , Catanzaro , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sarmiento</LastName>                    <ForeName>Roberta</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>u Oncology Unit , San Filippo Neri Hospital , Rome , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Graziano</LastName>                    <ForeName>Vincenzo</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>v Medical Oncology Unit , SS Annunziata Hospital , Chieti , Italy.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>w Breast Medical Oncology Unit , G. Bernabeo Hospital , Ortona , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Santini</LastName>                    <ForeName>Daniele</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>h Department of Oncology , University Campus Biomedico of Rome , Rome , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Marchetti</LastName>                    <ForeName>Paolo</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>j Department of Clinical and Molecular Medicine , &quot;Sapienza&quot; University of Rome, Azienda Ospedaliera Sant'Andrea , Rome , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tonini</LastName>                    <ForeName>Giuseppe</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>h Department of Oncology , University Campus Biomedico of Rome , Rome , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Di Lauro</LastName>                    <ForeName>Luigi</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>c Division of Medical Oncology 2 , IRCCS Regina Elena National Cancer Institute , Rome , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sanguineti</LastName>                    <ForeName>Giuseppe</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>x Department of Radiation Oncology , IRCCS Regina Elena National Cancer Institute , Rome , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Paoletti</LastName>                    <ForeName>Giancarlo</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>c Division of Medical Oncology 2 , IRCCS Regina Elena National Cancer Institute , Rome , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tomao</LastName>                    <ForeName>Silverio</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>g Medical Oncology Unit , Policlinico Umberto I , Rome , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>De Maria</LastName>                    <ForeName>Ruggero</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>y Institute of General Pathology , Catholic University of the Sacred Heart , Rome , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Veltri</LastName>                    <ForeName>Enzo</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>z Oncology Unit , S. Maria Goretti Hospital , Latina , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Paris</LastName>                    <ForeName>Ida</ForeName>                    <Initials>I</Initials>                    <AffiliationInfo>                        <Affiliation>aa Gynecology Oncology Unit , Catholic University of the Sacred Heart , Rome , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Giotta</LastName>                    <ForeName>Francesco</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>ab Department of Medical Oncology , &quot;Giovanni Paolo II&quot; Institute , Bari , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Latorre</LastName>                    <ForeName>Agnese</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>ab Department of Medical Oncology , &quot;Giovanni Paolo II&quot; Institute , Bari , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Giordano</LastName>                    <ForeName>Antonio</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>ac Center for Biotechnology , Sbarro Institute for Cancer Research and Molecular Medicine, College of Science and Technology, Temple University , Philadelphia , PA , USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ciliberto</LastName>                    <ForeName>Gennaro</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>f Scientific Direction , IRCCS Regina Elena National Cancer Institute , Rome , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Vici</LastName>                    <ForeName>Patrizia</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>c Division of Medical Oncology 2 , IRCCS Regina Elena National Cancer Institute , Rome , Italy.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>11</Month>                <Day>07</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Cancer Biol Ther</MedlineTA>            <NlmUniqueID>101137842</NlmUniqueID>            <ISSNLinking>1538-4047</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">HER2</Keyword>            <Keyword MajorTopicYN="N">endocrine therapy</Keyword>            <Keyword MajorTopicYN="N">first-line treatment</Keyword>            <Keyword MajorTopicYN="N">maintenance</Keyword>            <Keyword MajorTopicYN="N">metastatic breast cancer</Keyword>            <Keyword MajorTopicYN="N">pertuzumab</Keyword>            <Keyword MajorTopicYN="N">trastuzumab</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>8</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>8</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>8</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30403909</ArticleId>            <ArticleId IdType="doi">10.1080/15384047.2018.1523095</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>